Celltrion Inc And Celltrion Healthcare begin merger

Aug 17, 2023

Celltrion Group revealed in a corporate filing with the Repository of Korea’s Corporate Filings (DART) that Celltrion, Inc. and Celltrion Health Co., Ltd will merge as part of the initial phase of its merger plan.  Following this stage, the company will proceed with the second phase: a merger of Celltrion and Celltrion Pharm, Inc.  The company said the merger is expected to generate increased revenue through cost reduction and enhancement of cost competitiveness.  The company aims to reach 3.5 trillion KRW revenue and 1.6 trillion KRW EBITDA by 2024 and 12 trillion KRW revenue by 2030.

On 26 July 2023, Celltrion has applied to the Korean Ministry of Food and Drug Safety for marketing authorisation of its CT-P42, biosimilar to Regeneron’s Eylea® (aflibercept) for all of Eylea®’s indications approved in Korea.

Print Page Mail Article